137 related articles for article (PubMed ID: 20615193)
1. Contribution of three CYP3A isoforms to metabolism of R- and S-warfarin.
Jones DR; Kim SY; Boysen G; Yun CH; Miller GP
Drug Metab Lett; 2010 Dec; 4(4):213-9. PubMed ID: 20615193
[TBL] [Abstract][Full Text] [Related]
2. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
[TBL] [Abstract][Full Text] [Related]
3. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
4. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of R- and S-warfarin by CYP2C19 into four hydroxywarfarins.
Kim SY; Kang JY; Hartman JH; Park SH; Jones DR; Yun CH; Boysen G; Miller GP
Drug Metab Lett; 2012 Sep; 6(3):157-64. PubMed ID: 23331088
[TBL] [Abstract][Full Text] [Related]
6. Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes.
Moore CD; Roberts JK; Orton CR; Murai T; Fidler TP; Reilly CA; Ward RM; Yost GS
Drug Metab Dispos; 2013 Feb; 41(2):379-89. PubMed ID: 23143891
[TBL] [Abstract][Full Text] [Related]
7. Comparison of steroid hormone hydroxylation mediated by cytochrome P450 3A subfamilies.
Niwa T; Okamoto A; Narita K; Toyota M; Kato K; Kobayashi K; Sasaki S
Arch Biochem Biophys; 2020 Mar; 682():108283. PubMed ID: 32001245
[TBL] [Abstract][Full Text] [Related]
8. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'- and 10-hydroxywarfarin.
Ngui JS; Chen Q; Shou M; Wang RW; Stearns RA; Baillie TA; Tang W
Drug Metab Dispos; 2001 Jun; 29(6):877-86. PubMed ID: 11353757
[TBL] [Abstract][Full Text] [Related]
9. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
10. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates.
Galetin A; Brown C; Hallifax D; Ito K; Houston JB
Drug Metab Dispos; 2004 Dec; 32(12):1411-20. PubMed ID: 15342470
[TBL] [Abstract][Full Text] [Related]
11. Effect of ethanol on S-warfarin and diclofenac metabolism by recombinant human CYP2C9.1.
Tatsumi A; Ikegami Y; Morii R; Sugiyama M; Kadobayashi M; Iwakawa S
Biol Pharm Bull; 2009 Mar; 32(3):517-9. PubMed ID: 19252308
[TBL] [Abstract][Full Text] [Related]
12. Digging Deeper into CYP3A Testosterone Metabolism: Kinetic, Regioselectivity, and Stereoselectivity Differences between CYP3A4/5 and CYP3A7.
Kandel SE; Han LW; Mao Q; Lampe JN
Drug Metab Dispos; 2017 Dec; 45(12):1266-1275. PubMed ID: 28986474
[TBL] [Abstract][Full Text] [Related]
13. Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth.
Lacroix D; Sonnier M; Moncion A; Cheron G; Cresteil T
Eur J Biochem; 1997 Jul; 247(2):625-34. PubMed ID: 9266706
[TBL] [Abstract][Full Text] [Related]
14. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
15. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.
Shen L; Fitzloff JF; Cook CS
Drug Metab Dispos; 2004 Feb; 32(2):186-96. PubMed ID: 14744940
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Klees TM; Sheffels P; Dale O; Kharasch ED
Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
[TBL] [Abstract][Full Text] [Related]
17. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
[TBL] [Abstract][Full Text] [Related]
18. Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.
Neunzig I; Drăgan CA; Widjaja M; Schwaninger AE; Peters FT; Maurer HH; Bureik M
Biochim Biophys Acta; 2011 Jan; 1814(1):161-7. PubMed ID: 20637317
[TBL] [Abstract][Full Text] [Related]
19. Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells.
Ohmori S; Nakasa H; Asanome K; Kurose Y; Ishii I; Hosokawa M; Kitada M
Biochim Biophys Acta; 1998 May; 1380(3):297-304. PubMed ID: 9555064
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the biotransformation pathways of clomiphene, tamoxifen and toremifene as assessed by LC-MS/(MS) following in vitro and excretion studies.
Mazzarino M; Biava M; de la Torre X; Fiacco I; Botrè F
Anal Bioanal Chem; 2013 Jun; 405(16):5467-87. PubMed ID: 23604525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
